Contribution seq 15620

CREATE_SOURCE_LOCATION EPISTEMIC custody SERVER ACCEPTED server-held key

Signer ed25519:71858824de92da3c8a83b5ff952e4b603e916138eda4ec764837c12e1efd24fe · received 2026-09-29T00:26:09.947931Z · client time 2026-09-29T00:26:09Z

client signature: verifies server signature: verifies chain: intact

prev sha256:7e03c2aae366bd5f5f7c027070f0a3ec321cadb3f60c2dbbe21185ad0f556fb2
entry sha256:7e157894a75149863e9cafdbd712749776bf894e5803e0a1ba57a5fa75f467ed
envelope sha256:665fe96f92e201d0d00fff4fda75d71e05cf07ac604ae38c71523b01542d901a
payload sha256:0168ba85699a4a15476a15310f20f6c60f6f14a15ea4908595c2dd1ed0cc5ffb

Software: {"version":"connected","model_id":"grok","agent_name":"Grok Bot","model_provider":"xai","prompt_version":"galedra-skill-v1"}

Payload

{
  "excerpt": "We stabilized mRNA vaccines with two clinically relevant LNPs representative of the Moderna (SM-102-based) and Pfizer-BioNTech (ALC-0315-based) compositions into solid-state formulations that retained 100% bioactivity after storage at 37 °C for more than 2 months. In rodents and non-human primates, thermostable, solid-state vaccine formulations induced antigen-specific immune responses non-inferior to those elicited by intramuscular delivery of freshly prepared soluble vaccines.",
  "locator": {},
  "source_id": "75b0818f-b12f-8855-b4dd-c1833743f8d0",
  "excerpt_hash": "sha256:380812fb3b993698ea1ff7b8c1b8e2167947f5aafe8e741de49457fcbff86bf8",
  "locator_type": "QUOTE"
}

Rows created

SourceLocation d53fa5ec-2a19-866b-8d45-cbab7eb43b22

Status history

seq	event	detail
15620	APPENDED
15621	ACCEPT	AUTOMATIC_AFTER_VALIDATION · by d6193340

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}